Moderna (MRNA) Competitors

Robinhood Markets currently has a consensus target price of $110.18, suggesting a potential upside of 27.58%. Moderna has a consensus target price of $36.60, suggesting a potential downside of 20.42%. Given Robinhood Markets' stronger consensus rating and higher probable upside, equities analysts clearly believe Robinhood Markets is more favorable than Moderna.

Robinhood Markets has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Robinhood Markets, indicating that it is currently the more affordable of the two stocks.

Robinhood Markets has a beta of 2.35, suggesting that its share price is 135% more volatile than the broader market. Comparatively, Moderna has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market.

93.3% of Robinhood Markets shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 20.0% of Robinhood Markets shares are owned by insiders. Comparatively, 10.8% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Robinhood Markets has a net margin of 41.12% compared to Moderna's net margin of -143.55%. Robinhood Markets' return on equity of 21.39% beat Moderna's return on equity.

In the previous week, Robinhood Markets had 71 more articles in the media than Moderna. MarketBeat recorded 94 mentions for Robinhood Markets and 23 mentions for Moderna. Robinhood Markets' average media sentiment score of 0.82 beat Moderna's score of 0.49 indicating that Robinhood Markets is being referred to more favorably in the media.

Novavax has a net margin of -14.73% compared to Moderna's net margin of -143.55%. Novavax's return on equity of -14.82% beat Moderna's return on equity.

75.3% of Moderna shares are held by institutional investors. Comparatively, 53.0% of Novavax shares are held by institutional investors. 10.8% of Moderna shares are held by company insiders. Comparatively, 1.6% of Novavax shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Moderna has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market. Comparatively, Novavax has a beta of 2.45, suggesting that its share price is 145% more volatile than the broader market.

Novavax has lower revenue, but higher earnings than Moderna. Novavax is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Moderna presently has a consensus target price of $36.60, suggesting a potential downside of 20.42%. Novavax has a consensus target price of $12.13, suggesting a potential upside of 41.65%. Given Novavax's stronger consensus rating and higher probable upside, analysts plainly believe Novavax is more favorable than Moderna.

In the previous week, Moderna had 15 more articles in the media than Novavax. MarketBeat recorded 23 mentions for Moderna and 8 mentions for Novavax. Moderna's average media sentiment score of 0.49 beat Novavax's score of 0.33 indicating that Moderna is being referred to more favorably in the media.

Moderna has a net margin of -143.55% compared to Ocugen's net margin of -1,192.18%. Moderna's return on equity of -26.64% beat Ocugen's return on equity.

10.3% of Ocugen shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 4.0% of Ocugen shares are held by company insiders. Comparatively, 10.8% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Ocugen has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Ocugen presently has a consensus price target of $9.50, indicating a potential upside of 698.32%. Moderna has a consensus price target of $36.60, indicating a potential downside of 20.42%. Given Ocugen's stronger consensus rating and higher possible upside, equities research analysts plainly believe Ocugen is more favorable than Moderna.

In the previous week, Moderna had 19 more articles in the media than Ocugen. MarketBeat recorded 23 mentions for Moderna and 4 mentions for Ocugen. Ocugen's average media sentiment score of 0.52 beat Moderna's score of 0.49 indicating that Ocugen is being referred to more favorably in the media.

Ocugen has a beta of 2.19, meaning that its share price is 119% more volatile than the broader market. Comparatively, Moderna has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market.

Regeneron Pharmaceuticals presently has a consensus price target of $792.65, suggesting a potential upside of 31.75%. Moderna has a consensus price target of $36.60, suggesting a potential downside of 20.42%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Regeneron Pharmaceuticals is more favorable than Moderna.

Regeneron Pharmaceuticals has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market. Comparatively, Moderna has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market.

Regeneron Pharmaceuticals has a net margin of 29.65% compared to Moderna's net margin of -143.55%. Regeneron Pharmaceuticals' return on equity of 13.16% beat Moderna's return on equity.

83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are held by insiders. Comparatively, 10.8% of Moderna shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Regeneron Pharmaceuticals has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

In the previous week, Regeneron Pharmaceuticals had 23 more articles in the media than Moderna. MarketBeat recorded 46 mentions for Regeneron Pharmaceuticals and 23 mentions for Moderna. Regeneron Pharmaceuticals' average media sentiment score of 1.12 beat Moderna's score of 0.49 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media.